Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the ...

Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...

* Submission based on data from pivotal trials evaluating efficacy, safety and tolerability in patients suffering from schizophrenia * Lundbeck has co-development and co-commercialisation rights to ...

Otsuka and H. Lundbeck announced that the FDA has accepted for review its New Drug Application (NDA) for once-monthly aripiprazole depot formulation for the maintenance treatment of schizophrenia in ...

New Depot Formulations Will Command Premium Pricing and Their Sales Will Offset Those Lost to the Generic Erosion of Janssen’s Risperdal Consta, According to Findings from Decision Resources ...

Lundbeck chalked up its second piece of welcome product news this week after the US FDA approved a once-monthly version of its blockbuster schizophrenia treatment Abilify. Abilify Maintena ...

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...

Otsuka Pharmaceutical has taken an important step forward in the development of a once-monthly version of its blockbuster schizophrenia drug Abilify (aripiprazole). U.S. regulators have accepted for ...

Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...

Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...